fendiline has been researched along with Prostatic Neoplasms in 1 studies
Fendiline: Coronary vasodilator; inhibits calcium function in muscle cells in excitation-contraction coupling; proposed as antiarrhythmic and antianginal agents.
Prostatic Neoplasms: Tumors or cancer of the PROSTATE.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Jan, CR | 1 |
| Lee, KC | 1 |
| Chou, KJ | 1 |
| Cheng, JS | 1 |
| Wang, JL | 1 |
| Lo, YK | 1 |
| Chang, HT | 1 |
| Tang, KY | 1 |
| Yu, CC | 1 |
| Huang, JK | 1 |
1 other study available for fendiline and Prostatic Neoplasms
| Article | Year |
|---|---|
Fendiline, an anti-anginal drug, increases intracellular Ca2+ in PC3 human prostate cancer cells.
Topics: Adenosine Triphosphate; Calcium; Calcium Channel Blockers; Fendiline; Humans; Inositol 1,4,5-Trispho | 2001 |